Bridging the divide
DURHAM, N.C.—A new study detailed in STEM CELLS in a paper titled “cPLA2α reversibly regulate different subsets of cancer stem cells transformation in cervical cancer” identifies, for the first time, two morphologically and functionally different types of cancer stem cells found in cervical cancer. Of the two types, one exhibits an overexpression of cPLA2α, a key enzyme that triggers the transformation of dormant cancer stem cells into active ones, resulting in cervical cancer metastasis and recurrence.
The information in this study could lead to new targets for treatments to halt tumor recurrence and metastatic spread. Also, it might accelerate the development of combination therapies.
The current standard-of-care treatments for cervical cancer are radiotherapy and chemotherapy. However, the cancer’s resistance to these treatments, combined with a tendency to metastasize in the lymph nodes or recur in the pelvis, leaves doctors searching for more effective treatments.
Cervical cancer stem cells (CCSCs) are considered the major culprit behind the cancer’s ability to overcome these treatments. At the same time, a majority of cancer stem-like cells or tumor-initiating cells remain dormant. It takes a change in their microenvironment to spur them to metastasize.
“The mechanisms responsible for this must be identified to design more suitable therapies for the different subpopulations of cancer stem cells (CSCs) in various tissue-specific cancers,” said Dr. Hua Guo, who headed up the investigation along with Dr. Yuchao He. The two are colleagues at Tianjin Medical University Cancer Institute and Hospital. Researchers at Tianjin University of Traditional Chinese Medicine and at the Center for Translational Cancer Research, Peking University First Hospital, also participated in the study.
Although several cell surface antigens have been identified in CCSCs, these markers vary among tumors because of CSC heterogeneity. However, whether these markers specifically distinguish CCSCs with different functions is unclear. The study published in STEM CELLS sought to resolve this question, and its findings demonstrate that CCSCs exist in two biologically distinct phenotypes characterized by different levels of cPLA2α expression.
“Our study showed for the first time that overexpression of cPLA2α results in a phenotype associated with mesenchymal traits, including increased invasive and migration abilities. On the other hand, CCSCs with cPLA2α downregulation show dormant epithelial characteristics,” said Guo. “In addition, cPLA2α regulates the reversible transition between mesenchymal and epithelial CCSC states through PKCζ, an atypical protein that governs cancer cell state changes.”
Added He: “Now that we know cPLA2α triggers this transformation, we believe that cPLA2α might be an attractive therapeutic target for eradicating different states of CCSCs to eliminate tumors more effectively.”
“The novel study by Dr. Guo and team is of very high importance in understanding the transition between dormant cancer stem cells, which evade chemotherapy and radiation treatments, and actively dividing cells which can be better targeted,” said Dr. Jan Nolta, editor-in-chief of STEM CELLS. “I applaud the group for this important discovery which will help researchers develop better treatments for cervical cancer.”